Universe Pharmaceuticals INC Accounts Receivable
Universe Pharmaceuticals INC (UPC) had Accounts Receivable of $13.01 billion as of 2025-09-30, per its 20-F filed 2026-01-29.
Financial Statements › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-01-29
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $13.01B.
- 2024-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $12.91B; Accounts Receivable, after Allowance for Credit Loss, Current as first filed $12.91M.
- 2024-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $14.38M.
- 2023-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $11.01M; Accounts Receivable, after Allowance for Credit Loss, Current as first filed $10.67M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2025-09-30 | $13.01B 20-F · filed 2026-01-29 | |
| 2024-09-30 | $12.91B 20-F · filed 2026-01-29 | $12.91M 20-F · filed 2025-04-29 |
| 2024-03-31 | $14.38M 6-K · filed 2024-09-20 | |
| 2023-09-30 | $11.01M 20-F · filed 2025-04-29 | $10.67M 20-F · filed 2024-01-30 |
| 2023-03-31 | $17.52M 6-K · filed 2023-08-31 | |
| 2022-09-30 | $15.18M 20-F · filed 2024-01-30 | |
| 2022-03-31 | $18.82M 6-K · filed 2022-08-16 | |
| 2021-09-30 | $15.57M 20-F · filed 2023-02-10 | |
| 2020-09-30 | $10.87M 20-F · filed 2022-01-31 |